Inclusion Criteria:
* Understands and is willing to sign an Informed Consent, approved by the local Ethics Committee.
* Female or male, ages 18-95 years old (inclusive)
* Systemically healthy.
* Presence of at least three evaluable teeth in each quadrant.
* Moderate gingival inflammation, with at least a 10% of bleeding on probing (BOP) will be required together with moderate level of plaque.
* No Grade 3 Tooth Mobility
* Treated stage II or III periodontitis patients, whose active treatment has finalized more than 6 months before. Stage II - Interdental clinical attachment level (CAL) at the site of greatest loss equal to 3 to 4 millimeters with maximum probing depth of less than or equal to 5 millimeters. Stage III - Interdental CAL at the site of greatest loss greater than equal to 5 millimeters, probing depth (PD) greater than or equal to 6 millimeters, and radiographic vertical bone loss
* Enrolled in a periodontal maintenance treatment program
* No orthodontic banding (no permanent retainers, no orthodontic appliances (i.e., no removable plastic/metal retainer) or removable prosthesis (no removable partial and/or full denture).
* Subjects willing to participate and comply with the requirements of the study.
* Subjects that brush their teeth regularly (once or twice daily).
* Able to travel to and attend 4 research study visits over the span of the next 6 months.
* Able to independently provide consent for oneself.
* Fluent in reading, comprehending, and speaking English without assistance from a translator.
* If a patient is using prevident, they must be willing to stop using it.
Exclusion Criteria:
* Untreated or uncontrolled periodontitis or advanced (advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive alveolar bone loss)
* Antibiotics intake within the previous month.
* Pregnant women and/or breastfeeding women
* Any adverse medical history (controlled and uncontrolled diabetes, osteoporosis, immunosuppression…) or long-term medication (chemotherapy and immunosuppression treatment; pharmacological treatment associated with gingival overgrowth such as the use of phenytoin, phenobarbital, lamotrigine, vigabatrin, ethosuximide, topiramate, primidone, nifedipine, amlodipine, verapamil, cyclosporine) influencing gingival conditions.
* Conditions which require antibiotic prophylaxis (infectious endocarditis, cardiac valve prosthesis…).
* Not willing to comply with the study protocol recommendation and visit schedule.
* Current smokers or those using tobacco or vaping products.
* Five (5) or more decayed, untreated dental sites (cavities) and/or any dental condition requiring urgent dental care
* Currently participating in another clinical research study now and/or within the past month.
* Has a history of allergies to oral care or personal care consumer products or their ingredients
* Has an existing medical condition that prohibits eating or drinking for periods up to 4 hours.
* Any ongoing medical condition that makes a subject unsuitable for enrollment-or any new diagnosis that arises during the study that makes the subject unsuitable to continue-may lead to exclusion, as determined by the Principal Investigator on a case by case basis. Conditions that may result in exclusion include, but are not limited to:
1. Recent myocardial infarction
2. Recent cerebrovascular accident
3. Recent placement of a cardiac valvular prosthesis
4. Severe liver dysfunction
5. Known or suspected current malignancy
6. New antibiotic use
7. Note: The Principal Investigator will review all available information about the subject and make decisions regarding both enrollment and/or continued participation.
